foxo4-dri senolytic 2023 2024 study

foxo4-dri senolytic 2023 2024 study Frontiers Peptide inhibitors targeting FOXO4-p53 interactions

Name: foxo4-dri senolytic 2023 2024 study Frontiers Peptide inhibitors targeting FOXO4-p53 interactions
Brand: webdevsolutions.tech
SKU: 77306427750
Price: 22.75 USD
Availability: InStock
Rating: 4.495 (18 reviews)

Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC

SKU: 77306427750 · From webdevsolutions.tech

4.5

USD22.75 USD64.75

Pay in 4 interest-free payments of $5.69 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 15 - Aug 20

Description

British Journal of Pharmacology / NIHMS PMC (2008) 6

Cancer Biology & Therapy, 11 (9), 777-792

According to various sources: Some vendor specifications list a shelf life of 24 months (2 years) when properly stored

GHK-Cu 100 mg Research Grade GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine : copper) widely studied in skin-remodeling, wound-repair, and tissue-regeneration research models